NCLEX Review Guide: Erythroblastosis Fetalis

Definition and Mechanism

• Erythroblastosis fetalis, also known as hemolytic disease of the newborn (HDN), is a condition where maternal antibodies cross the placenta and attack fetal red blood cells causing hemolysis. The most common form occurs when an Rh-negative mother develops antibodies against the Rh-positive red blood cells of her fetus.
• The process begins when fetal Rh-positive blood cells enter the maternal circulation (typically during delivery, miscarriage, abortion, trauma, or invasive procedures), triggering the production of anti-Rh antibodies in the Rh-negative mother. In subsequent pregnancies with an Rh-positive fetus, these antibodies cross the placenta and destroy fetal red blood cells.

Types of Incompatibility

• Rh Incompatibility: Occurs when an Rh-negative mother carries an Rh-positive fetus. The most severe form of erythroblastosis fetalis typically develops after maternal sensitization has occurred during a previous pregnancy.
• ABO Incompatibility: Occurs most commonly when a mother with type O blood carries a fetus with type A or B blood. ABO incompatibility is generally less severe than Rh incompatibility but is more common and can occur during first pregnancies.

Signs and Symptoms

• Jaundice: Yellowing of the skin and sclera typically appears within the first 24 hours after birth in severe cases (pathologic jaundice). This early onset differentiates it from physiologic jaundice, which typically appears after 24 hours.
• Anemia: Due to hemolysis of fetal red blood cells, resulting in pallor, tachycardia, and poor feeding.
• Hepatosplenomegaly: Enlarged liver and spleen due to increased production of red blood cells and destruction of antibody-coated RBCs.
• Hydrops Fetalis: The most severe manifestation, characterized by generalized edema, ascites, pleural and pericardial effusions, and heart failure. This represents end-stage disease and has a high mortality rate.

Diagnostic Tests

• Blood Typing and Rh Factor: Determines the blood type and Rh status of both mother and newborn to identify incompatibility.
• Direct Coombs Test (DCT): Detects antibodies attached to the surface of the infant's red blood cells. A positive result indicates hemolytic disease.
• Indirect Coombs Test: Detects maternal antibodies circulating in the mother's serum that could potentially cause hemolysis in the fetus.
• Complete Blood Count (CBC): Evaluates hemoglobin, hematocrit, and reticulocyte count to assess the degree of anemia and the bone marrow's response.
• Bilirubin Levels: Total and direct bilirubin levels help determine the severity of jaundice and guide treatment decisions.

Antenatal Diagnosis

• Maternal Antibody Titers: Monitoring anti-Rh antibody levels during pregnancy helps assess the risk of fetal hemolytic disease. Rising titers (typically >1:16) suggest significant risk.
• Middle Cerebral Artery Doppler: Used to detect fetal anemia by measuring peak systolic velocity in the middle cerebral artery. Increased velocity indicates fetal anemia.
• Amniocentesis: Analysis of amniotic fluid for bilirubin levels (measured as optical density at 450 nm) helps predict the severity of hemolytic disease.
• Percutaneous Umbilical Blood Sampling (PUBS): Direct sampling of fetal blood to assess hemoglobin, hematocrit, and blood type. This is the most accurate method but carries higher risks.

Prevention

• Rh Immune Globulin (RhoGAM): Administered to Rh-negative mothers to prevent sensitization. The antibodies in RhoGAM destroy any fetal Rh-positive cells in the maternal circulation before the mother's immune system can respond.
• RhoGAM is typically given at 28 weeks gestation, within 72 hours after delivery of an Rh-positive infant, and after any event that could cause fetal-maternal hemorrhage (miscarriage, abortion, amniocentesis, etc.).

Antenatal Management

• Intrauterine Transfusion (IUT): Direct transfusion of Rh-negative, cross-matched red blood cells into the fetal circulation (usually via the umbilical vein) to treat severe fetal anemia.
• Early Delivery: When the fetus has reached sufficient maturity and the risks of continued pregnancy outweigh the risks of prematurity, early delivery may be indicated.

Postnatal Management

• Phototherapy: Uses special blue lights to convert unconjugated bilirubin into water-soluble isomers that can be excreted without liver conjugation.
• Exchange Transfusion: Removes antibody-coated red blood cells and bilirubin while replacing them with donor red blood cells. Indicated for severe anemia or rapidly rising bilirubin levels despite phototherapy.
• Intravenous Immunoglobulin (IVIG): May reduce hemolysis by blocking Fc receptors on reticuloendothelial cells, preventing them from destroying antibody-coated red blood cells.

Exchange Transfusion Procedure

1. Obtain appropriate blood products (typically type O, Rh-negative, cross-matched with mother's serum)
2. Insert umbilical venous and arterial catheters under sterile conditions
3. Remove small aliquots of the infant's blood (usually 5-10 mL)
4. Replace with equal volumes of donor blood
5. Continue the process until approximately twice the infant's blood volume has been exchanged
6. Monitor vital signs, blood glucose, electrolytes, and calcium throughout the procedure
7. Check post-exchange hematocrit and bilirubin levels

Assessment

• Perform thorough maternal history to identify risk factors: Rh status, previous pregnancies with HDN, history of blood transfusions, or procedures during pregnancy.
• Assess newborn for jaundice using appropriate technique: press skin with finger to blanch the area and observe for yellow discoloration. Check sclera, mucous membranes, and skin, progressing from head to toe.
• Monitor vital signs, especially heart rate, for signs of anemia and cardiac compromise.
• Assess for signs of neurological involvement: lethargy, poor feeding, high-pitched cry, hypertonia or hypotonia, and opisthotonus (arching of the back).

Nursing Interventions

• Phototherapy Management: Position infant properly with maximum skin exposure; change position every 2 hours; protect eyes with opaque eye shields; monitor skin integrity, temperature, and hydration status.
• Exchange Transfusion Support: Assist with procedure preparation; monitor vital signs, glucose, and calcium levels; observe for complications; provide comfort measures.
• Nutritional Support: Encourage frequent feeding to promote intestinal motility and bilirubin excretion; monitor weight and intake/output; assess for dehydration.
• Parent Education: Explain the condition, treatment rationale, and expected outcomes; teach home care if applicable; emphasize the importance of follow-up and future pregnancy planning.

Erythroblastosis Fetalis vs. Other Causes of Neonatal Jaundice

RhoGAM vs. Other Blood Products

Key Concepts to Remember

NCLEX Question Strategies

• When answering questions about erythroblastosis fetalis, remember that prevention (RhoGAM) is always better than treatment. Look for options that address prophylaxis for at-risk mothers.
• For treatment questions, prioritize interventions that address immediate threats to life or neurological function (e.g., severe hyperbilirubinemia requiring exchange transfusion).
• When presented with assessment findings, differentiate between physiologic and pathologic jaundice based on timing of onset, progression, and associated findings.

• Erythroblastosis fetalis results from maternal-fetal blood group incompatibility, most commonly Rh or ABO incompatibility, causing hemolysis of fetal red blood cells.
• Rh incompatibility typically affects subsequent pregnancies after maternal sensitization, while ABO incompatibility can affect first pregnancies but is usually less severe.
• Clinical manifestations range from mild jaundice and anemia to severe hydrops fetalis with multi-organ failure.
• Diagnosis involves blood typing, Coombs testing, CBC, and bilirubin levels. Antenatal diagnosis uses maternal antibody titers, MCA Doppler, and sometimes amniocentesis or PUBS.
• Prevention of Rh sensitization with RhoGAM is highly effective when administered at appropriate times (28 weeks gestation, within 72 hours postpartum, and after potential sensitizing events).
• Treatment includes phototherapy, exchange transfusion, IVIG, and supportive care. Intrauterine transfusions may be needed for severe fetal anemia.
• Early identification of at-risk infants and prompt treatment are essential to prevent kernicterus and permanent neurological damage.
• Nursing care focuses on monitoring for complications, supporting treatments, and educating parents about the condition and future pregnancy planning.